Andrea Buschiazzo, MD, MBA, is a Senior Medical Director at Fortrea, a Board-Certified Rheumatologist and a Clinical Pharmacologist (University of Buenos Ares). At Fortrea, she offers therapeutic area expertise in inflammation and autoimmune diseases as well as global clinical development. 

Dr. Buschiazzo is based in Buenos Aires, Argentina, and provides medical leadership on projects teams, medical/scientific consultation and therapeutic expertise globally. She oversees study specific medical/safety monitoring activities, ensuring compliance with ethical, legal and regulatory standards as well as Fortrea and Sponsor SOPs, representing the Medical Affairs department in business development activities. 

She started her pharmaceutical career with Merck Sharp & Dohme in Medical & Scientific Affairs and Clinical Development, working in multiple therapeutic areas as an Associate Director before moving to a regional clinical development leader role at Servier for LATAM. Later, she worked at Kendle (then INC) as a Global Project Director and was responsible for successful development programs leading to registration of several innovative products before becoming a Managing Director at ICON. 

Dr. Buschiazzo has 33 years of experience in the pharmaceutical and CRO industry and 34 years in clinical practice. She completed a fellowship in autoimmune diseases at the Clinic Hospital in Barcelona. She published many articles and posted abstracts at the main Rheumatology Congresses (ACR/EULAR/SAR). 

She has provided global medical monitoring services and therapeutic advisory in almost all autoimmune diseases including Systemic Sclerosis, Rheumatoid Arthritis, Gout, Psoriatic Arthritis, Spondyloarthritis, Paget’s disease, Sjögren’s Syndrome, Vasculitis, Juvenile Arthritis, Osteoporosis, Osteoarthritis and Fibromyalgia. She has experience as Global Project Director and Medical Monitor for 10 Lupus studies, including Lupus Nephritis (Phase II-III) and the trials running prior to the approval of belimumab as the first biologic for SLE.

Alvin Tan is a Director of Strategy Delivery & Growth for Infectious Diseases and Critical Care and is based in Singapore. Alvin has more than 20 years of clinical development experience across operational delivery and global project management, covering all phases of research. He is trained in pharmacology and started as CRA, CRM and PD with increasing responsibility in regional project management and clinical operations to his current position with responsibility to provide operational strategy and planning for studies regionally and globally. He brings extensive experience in designing clinical trial strategy and recommending operational success factors and site selection across multiple therapeutic areas. He aggregates expertise of peers to create value for customers in supporting them to bring innovative medicines to patients faster and efficiently. Alvin joined our company in 2022.

Dr. Chng has more than 15 years of drug development industry experience across broad indications including neuroscience. She has extensive experience supporting small and medium sized biotech companies in Asia-Pac to develop their assets from early phase development to late clinical phases. With her project management skills, Dr. Chng is able to provide and advise operational strategy to Asia-Pac clients and help expand their drug development outside of the Asia-Pac region. Her therapeutic knowledge encompasses neurodegenerative, rare neurology indications as well as psychiatry disease, with a particular focus on schizophrenia.

Dr. Fuller has more than 20 years drug discovery and development experience across neuroscience, immunology and inflammation indications. Her 14 years clinical research experience across Phase I-III studies includes 11 years at Fortrea (formerly Labcorp and Covance), where she has supported development and implementation of Phase I and II clinical trials in patients with neurodegenerative diseases including Alzheimer’s disease. Dr. Fuller earned her Doctorate of Pharmacology from Northwestern Feinberg School of Medicine with a focus on Alzheimer’s drug discovery and development.